Document Detail

Erythropoietin ameliorates damage to the placenta and fetal liver induced by exposure to lipopolysaccharide.
MedLine Citation:
PMID:  20106521     Owner:  NLM     Status:  MEDLINE    
Intrauterine infection and inflammation have been causally linked to preterm birth and fetal brain injury. Using an ovine model of endotoxin-induced brain injury we have recently shown that recombinant human erythropoietin (rhEPO) reduces brain injury and protects against damage to myelination in major myelinated axon tracts. Our present objective was to determine whether rhEPO is also protective of the placenta and the fetal liver, organs which could influence fetal well-being. At 107 +/- 1 days of gestational age (DGA) chronically catheterized fetal sheep were randomly assigned to receive, on 3 consecutive days, either: 1) an i.v. bolus dose of lipopolysaccharide (LPS; approximately 0.9 microg/kg; n = 8); 2) i.v. bolus dose of LPS, followed at 1 h by 5000 IU/kg of rhEPO (LPS + rhEPO, n = 8); 3) rhEPO (n = 3). Seven untreated fetuses served as controls (n = 7). The placenta and fetal liver were examined histologically at 116 +/- 1 DGA; a placental injury index was formulated comprising measures of placental area, apoptosis, tissue injury and the size of the intervillous space. In LPS-exposed fetuses this index was greater than in control or rhEPO alone fetuses (p < 0.02). Treatment of LPS-exposed fetuses with rhEPO resulted in a reduction in the index (p < 0.05) and in the extent of liver necrosis. We conclude that rhEPO offers protection to the placenta and fetal liver in the presence of acute inflammation.
F Dijkstra; M Jozwiak; R De Matteo; J Duncan; N Hale; R Harding; S Rees
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-01-27
Journal Detail:
Title:  Placenta     Volume:  31     ISSN:  1532-3102     ISO Abbreviation:  Placenta     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-04-12     Completed Date:  2010-06-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8006349     Medline TA:  Placenta     Country:  England    
Other Details:
Languages:  eng     Pagination:  282-8     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier Ltd. All rights reserved.
Department of Anatomy and Cell Biology, University of Melbourne, Parkville 3010, Victoria, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Erythropoietin, Recombinant / therapeutic use*
Fetus / drug effects
Inflammation / prevention & control
Lipopolysaccharides / adverse effects*
Liver / drug effects*
Necrosis / prevention & control
Placenta / drug effects*,  pathology
Reg. No./Substance:
0/Erythropoietin, Recombinant; 0/Lipopolysaccharides

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Quantification of the binding affinity of a specific hydroxyapatite binding peptide.
Next Document:  Unique Properties of Decidual T Cells and their Role in Immune Regulation during Human Pregnancy.